使用带有多巴胺悬挂的抗氧化共聚物抑制胰岛素粉样纤维生成
Tamanna Mallick1, Anushree Mondal1, Shubham Das2
1Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, Nadia, West Bengal, 741246, India.
Small (Weinheim an der Bergstrasse, Germany)
|March 20, 2025
概括
研究人员开发了水溶性多巴胺基共聚物来对抗粉样蛋白聚合,这是神经退行性疾病的标志. DP3共聚合物在防止蛋白质误折叠和纤维细胞形成方面取得了显著的成功.
科学领域:
- 生物化学 生物化学
- 聚合物科学 聚合物科学
- 神经科学是一个神经科学.
背景情况:
- 粉样蛋白聚合与神经退行性和代谢性疾病有关.
- 多巴胺具有抗氧化和抗粉原性质,但溶解性较差.
- 目前针对粉样蛋白相关疾病的治疗方法有限.
研究的目的:
- 为了合成和评估可溶于水的多巴胺基共聚物 (DP1-DP3) 抑制粉样纤维的形成.
- 评估这些共聚物对胰岛素和粉样β (Aβ42) 纤维化的疗效.
- 探索多巴胺基聚合物的潜力,作为治疗amyloidogenic疾病的治疗剂.
主要方法:
- 用多巴胺和葡萄糖侧链悬挂制造水溶性共聚合物.
- 使用生物物理技术评估粉样纤维化抑制.
- 异热定位热量计 (ITC) 和光结合实验,以研究蛋白质-共聚物相互作用.
- 分子动力学模拟以验证抗粉原效应.
主要成果:
- DP1-DP3共聚合物表现出极好的激素清除特性.
- 该DP3共聚合物显示显著抑制 (≈97%) 的胰岛素粉样纤维化.
- 据模拟证实,DP3在预防胰岛素和Aβ42的粉样纤维化发生方面表现出有效性.
- 观察到DP3和氨基原蛋白/之间的有益相互作用.
结论:
- 基于多巴胺的抗氧化聚合物有效防止粉样蛋白聚合.
- DP3共聚合物在粉原性疾病中具有很高的治疗应用潜力.
- 这些发现凸显了新型聚合物设计应对蛋白质错折疾病的前景.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
329
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
329
Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148


